
    
      This is a multicenter, prospective and open-enrollment epidemiologic study. All the patients
      with liver biopsy-proven macrovesicular steatosis (>5%) will be enrolled in the baseline
      cross-sectional analysis. Those who are either diagnosed as NAFLD or ALD, if meeting all the
      inclusion and exclusion criteria, will be enrolled in the following cohort study, will be
      followed up after 1 year, 3 years and 5 years with a visit window of +1 month.
    
  